AB Initio Biotherapeutics

At Ab Initio, we are using a proprietary directed evolution engineering technology to create next-generation biologics, including antibodies that modulate the signaling activity of G-protein coupled receptors (GPCRs).

Focus area
Oncology
Commencement date
04/01/2015